RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation
Robert A. Jones, … , Aaron Schimmer, Eldad Zacksenhaus
Robert A. Jones, … , Aaron Schimmer, Eldad Zacksenhaus
Published October 3, 2016; First published August 29, 2016
Citation Information: J Clin Invest. 2016;126(10):3739-3757. https://doi.org/10.1172/JCI81568.
View: Text | PDF
Research Article Oncology

RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation

Abstract

Triple-negative breast cancer (TNBC) includes basal-like and claudin-low subtypes for which no specific treatment is currently available. Although the retinoblastoma tumor-suppressor gene (RB1) is frequently lost together with TP53 in TNBC, it is not directly targetable. There is thus great interest in identifying vulnerabilities downstream of RB1 that can be therapeutically exploited. Here, we determined that combined inactivation of murine Rb and p53 in diverse mammary epithelial cells induced claudin-low–like TNBC with Met, Birc2/3-Mmp13-Yap1, and Pvt1-Myc amplifications. Gene set enrichment analysis revealed that Rb/p53-deficient tumors showed elevated expression of the mitochondrial protein translation (MPT) gene pathway relative to tumors harboring p53 deletion alone. Accordingly, bioinformatic, functional, and biochemical analyses showed that RB1-E2F complexes bind to MPT gene promoters to regulate transcription and control MPT. Additionally, a screen of US Food and Drug Administration–approved (FDA-approved) drugs identified the MPT antagonist tigecycline (TIG) as a potent inhibitor of Rb/p53-deficient tumor cell proliferation. TIG preferentially suppressed RB1-deficient TNBC cell proliferation, targeted both the bulk and cancer stem cell fraction, and strongly attenuated xenograft growth. It also cooperated with sulfasalazine, an FDA-approved inhibitor of cystine xCT antiporter, in culture and xenograft assays. Our results suggest that RB1 deficiency promotes cancer cell proliferation in part by enhancing mitochondrial function and identify TIG as a clinically approved drug for RB1-deficient TNBC.

Authors

Robert A. Jones, Tyler J. Robinson, Jeff C. Liu, Mariusz Shrestha, Veronique Voisin, YoungJun Ju, Philip E.D. Chung, Giovanna Pellecchia, Victoria L. Fell, SooIn Bae, Lakshmi Muthuswamy, Alessandro Datti, Sean E. Egan, Zhe Jiang, Gustavo Leone, Gary D. Bader, Aaron Schimmer, Eldad Zacksenhaus

×

Figure 9

Effects of TIG and SSZ on RB1/TP53-deficient TNBC cell lines.

Options: View larger image (or click on image) Download as PowerPoint
Effects of TIG and SSZ on RB1/TP53-deficient TNBC cell lines. (A) MTT as...
(A) MTT assays on RB1-proficient and RB1-deficient TNBC lines treated with the indicated concentrations of TIG; SSZ was used at a dose of 500 μM for Hs578t and 300 μM for MDA-MB-436, MDA-MB-231, and BT549 cells. n = 3–5, each performed in triplicate. (B) ROS in TNBC cells 72 hours after treatment with IC50 for each line. n = 3; 10,000 events each. **P < 0.01 and #P = ~0.1 , by 2-tailed t test. (C) Representative apoptosis assays by annexin V flow cytometry depicting the live-cell fraction 72 hours after treatment with IC50 drug concentrations. n = 3; 10,000 events each. (D) CD24–ESA+CD44+ CSC fractions in TNBC lines 72, 120, and 168 hours after treatment using IC50.